Search
Wantai Biological proudly announces the marketing approval of its independently developed, domestically produced nine-valent HPV vaccine, Cecolin 9, marking it as the world's second such vaccine. Cecolin 9 offers protection against nine HPV types and is suitable for women aged 9 to 45. The vaccination regimen varies, with two or three doses administered depending on age group. Extensive research has demonstrated that Cecolin 9 is on par with imported vaccines in terms of immunogenicity and safety, offering equivalent protective efficacy, while potentially being more price-competitive. Large-scale clinical trials have revealed that Cecolin 9 boasts a protection rate exceeding 98% against persistent infections associated with multiple HPV types and achieves a 100% protection rate against cervical infections.
-
C114 Communication Network -
Communication Home
